Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05852938 · ClinicalTrials.gov registry record · Phase 3
A Study of Zigakibart in Adults With IgA Nephropathy
A Phase 3 study of Immunoglobulin A Nephropathy and IgA Nephropathy, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 383
- Enrollment target
- 20
- Study locations
NCT05852938 is a Phase 3 study of Immunoglobulin A Nephropathy and IgA Nephropathy that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 383 participants, above the 275-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05852938, a Phase 3 study of Immunoglobulin A Nephropathy and IgA Nephropathy, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 383 participants
- Enrollment target
- 20
- Study locations
Study Summary
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BION-1301
Study Locations (20)
New York
- Capital District Renal Physicians - Clifton Park
- Nephrology Associates PC - Flushing - Flushing
- Icahn School of Medicine at Mount Sinai - New York
Alabama
- University of Alabama at Birmingham: The Kirklin Clinic - Birmingham
- Nephrology Consultants, LLC - Huntsville
California
- University of California, San Francisco - San Francisco
- Valiance Clinical Research - South Gate
Colorado
- University of Colorado Hospital - Aurora
- Denver Nephrology Research Division - Denver
Illinois
- NorthShore University HealthSystem - Evanston
- Nephrology Associales of Northern Illinois and Indiana - Hinsdale
Ohio
- University of Cincinnati College of Medicine - 231 Albert Sabin Way - Cincinnati
- Cleveland Clinic-9500 Euclid Ave - Cleveland
Florida
- Vida Medical Centers - Pembroke Pines - Pembroke Pines
Indiana
- Nephrology Associates of Northern Illinois and Indiana - 7836 W Jefferson Blvd - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2028-06-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05852938
The ClinicalTrials.gov registry entry for NCT05852938 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 275-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (39% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05852938 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05852938 about?
NCT05852938 is a clinical study titled "A Study of Zigakibart in Adults With IgA Nephropathy". Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
What is the current status of trial NCT05852938?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 383 participants. The study started on 2023-07-06. Estimated completion is 2028-06-07.
What conditions does trial NCT05852938 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy, IgA Nephropathy.
What interventions are being tested in trial NCT05852938?
The interventions under investigation include: Placebo (DRUG), BION-1301 (DRUG).
Who is sponsoring clinical trial NCT05852938?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05852938 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.